Results 141 to 150 of about 1,837 (187)
The pharmacokinetics of oxypurinol in people with gout [PDF]
British Journal of Clinical Pharmacology, 2012 WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Response to allopurinol in patients with gout is often suboptimal due to large variability in pharmacokinetics.• The sources of the variability in oxypurinol pharmacokinetics have not been systematically identified and quantified.• A therapeutic target 15–23 mg l−1for oxypurinol concentrations has recently been
Sophie L Stocker +2 more
exaly +8 more sources
The population pharmacokinetics of allopurinol and oxypurinol in patients with gout
European Journal of Clinical Pharmacology, 2013 The aims of this study were to develop a population pharmacokinetic model for allopurinol and oxypurinol and to explore the influence of patient characteristics on allopurinol and oxypurinol pharmacokinetics.Data from 92 patients with gout and 12 healthy volunteers were available for analysis.
Daniel F B Wright +2 more
exaly +4 more sources
Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation [PDF]
Experimental Cell Research, 2016 Allopurinol and its active metabolite, oxypurinol are widely used in the treatment of gout and hyperuricemia. They inhibit xanthine oxidase (XO) an enzyme in the purine degradation pathway that converts xanthine to uric acid. This investigation examined the effect of allopurinol and oxypurinol on bone formation, cell number and viability, gene ...
Isabel R Orriss +2 more
exaly +6 more sources
Oxidative and nitrosative stress in acute pancreatitis. Modulation by pentoxifylline and oxypurinol
Biochemical Pharmacology, 2012 Reactive oxygen species are considered mediators of the inflammatory response and tissue damage in acute pancreatitis. We previously found that the combined treatment with oxypurinol - as inhibitor of xanthine oxidase- and pentoxifylline - as inhibitor of TNF-α production-restrained local and systemic inflammatory response and decreased mortality in ...
Javier Escobar +2 more
exaly +6 more sources
The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout
NephrologyAbstract Gout affects 15%–30% of individuals with advanced kidney disease. Allopurinol which is rapidly and extensively metabolised to an active metabolite, oxypurinol, is the most commonly prescribed urate‐lowering therapy. Oxypurinol is almost entirely eliminated by the kidneys (>95%) and has an elimination half‐life of 18–30 h in those with normal ...
Luke C Wilson +2 more
exaly +4 more sources
Measurement of urinary oxypurinol by high performance liquid chromatography–tandem mass spectrometry
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010 Oxypurinol is the active metabolite of allopurinol which is used to treat hyperuricaemia associated with gout. Both oxypurinol and allopurinol inhibit xanthine oxidase which forms uric acid from xanthine and hypoxanthine. Plasma oxypurinol concentrations
Sophie L Stocker +2 more
exaly +2 more sources
Effect of Oxypurinol on Renal Reperfusion Injury in the Rat
Renal Failure, 1993 Oxygen-based free radicals produced by the enzyme xanthine oxidase may be involved in postischemic reperfusion injury. To determine whether oxypurinol, a xanthine oxidase inhibitor and the major metabolite of allopurinol, attenuates renal ischemic reperfusion injury, and, if so, to determine its most effective dose, oxypurinol 2.5, 5, 10 or 20 mg/kg BW
William F Finn
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Oxypurinol attenuates ischemia-induced hippocampal damage in the gerbil
Brain Research Bulletin, 1989Oxypurinol, an inhibitor of the enzyme xanthine oxidase, reduced ischemic hippocampal damage and the associated hypermotility in Mongolian gerbils. Cerebral ischemia was induced in unanesthetized gerbils by a bilateral 5-min occlusion of the carotid arteries.
J W Phillis, J W Phillis
exaly +3 more sources
An allopurinol adherence tool using plasma oxypurinol concentrations
British Journal of Clinical Pharmacology, 2022AbstractAimsThis study aimed to develop and evaluate an allopurinol adherence tool based on steady‐state oxypurinol plasma concentrations, allopurinol's active metabolite.MethodsPlasma oxypurinol concentrations were simulated stochastically from an oxypurinol pharmacokinetic model for allopurinol doses of 100‐800 mg daily, accounting for differences in
Natalia Smith‐Diaz +6 more
openaire +2 more sources
Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol
Clinical Pharmacokinetics, 2007Allopurinol is the drug most widely used to lower the blood concentrations of urate and, therefore, to decrease the number of repeated attacks of gout. Allopurinol is rapidly and extensively metabolised to oxypurinol (oxipurinol), and the hypouricaemic efficacy of allopurinol is due very largely to this metabolite.
Richard O, Day +5 more
openaire +2 more sources